| Autor: |
Popescu MC; XEME Biopharma, Plainsboro, NJ 08536, USA. mpopescu@xemebiopharma.com, Robb RJ, Batenjany MM, Boni LT, Neville ME, Pennington RW, Neelapu SS, Kwak LW |
| Jazyk: |
angličtina |
| Zdroj: |
Blood [Blood] 2007 Jun 15; Vol. 109 (12), pp. 5407-10. Date of Electronic Publication: 2007 Mar 09. |
| DOI: |
10.1182/blood-2006-08-039446 |
| Abstrakt: |
Therapeutic vaccination against idiotype is a promising strategy for immunotherapy of B-cell malignancies. Its feasibility, however, is limited by the requirement for a patient-specific product. Here we describe a novel vaccine formulation prepared by simply extracting cell-membrane proteins from lymphoma cells and incorporating them together with IL-2 into proteoliposomes. The vaccine was produced in 24 hours, compared with more labor-intensive and time-consuming hybridoma or recombinant DNA methods. The vaccine elicited T-cell immunity in vivo, as demonstrated by secretion of type 1 cytokines. It protected against tumor challenge at doses of tumor antigen 50 to 100 times lower than that previously observed using either liposomes formulated with IL-2 and secreted lymphoma immunoglobulin or a prototype vaccine consisting of lymphoma immunoglobulin conjugated to keyhole limpet hemocyanin. The increased potency justifies testing similar patient-specific human vaccines prepared using extracts from primary tumor samples. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
